Huang HK, Liu PPS, Hsu JY, et al. - Using Taiwan's National Health Insurance Research Database, researchers undertook this nationwide, retrospective cohort study to compare the risk of osteoporosis in relation to treatment with non–vitamin K antagonist oral anticoagulants (NOACs) or warfarin in patients with atrial fibrillation. Further classification of patients treated with NOACs, into the rivaroxaban, dabigatran, and apixaban subgroups, was done. For each head-to-head comparison, they performed propensity score matching. This study included 17,008 patients, with 8,504 in each cohort. Findings revealed a significantly lower risk of osteoporosis in relation to rivaroxaban and apixaban, vs warfarin, in patients with atrial fibrillation.